Lexicon and Ipsen's telotristat etiprate Phase III trial meets primary endpoint

USA-based Lexicon Pharmaceuticals (Nasdaq: LXRX) and its partner French drugmaker Ipsen (Euronext: IPN) have announced positive results from their TELESTAR Phase III clinical trial of oral telotristat etiprate.

The trial examined telotristat etiprate in treating cancer patients with carcinoid syndrome that is not adequately controlled by the current standard of care. It is the first treatment discovered by Lexicon to complete a pivotal Phase III trial. If approved, it would be the first oral treatment successfully developed for carcinoid syndrome, and the first addition to standard of care in 16 years.

Top-line data from the study showed patients who added telotristat etiprate to the standard of care at 250mg and 500mg doses experienced a statistically-significant reduction from baseline compared to placebo in the average number of daily bowel movements over the 12-week study period, meeting the study’s primary endpoint.